RPL31P63: A Promising Drug Target / Biomarker (G100271392)

Target Name: RPL31P63

NCBI ID: G100271392

RPL31P63

Other Name(s): Ribosomal protein L31 pseudogene 63 | RPL31_36_1782 | ribosomal protein L31 pseudogene 63

RPL31P63: A Promising Drug Target / Biomarker

Rpl31p63 is a gene located on chromosome 17 that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein encoded by Rpl31p63 is involved in a variety of cellular processes, including cell adhesion, migration, and survival.

Disease-related functions of Rpl31p63

Rpl31p63 has been shown to be involved in several disease-related processes, including cancer, neurodegenerative diseases, and autoimmune disorders.

1. Cancer

Rpl31p63 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. Studies have shown that high levels of Rpl31p63 are associated with poor prognosis in cancer patients.

2. Neurodegenerative diseases

Rpl31p63 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Studies have shown that Rpl31p63 levels are higher in individuals with neurodegenerative diseases and that targeting Rpl31p63 may be a potential therapy.

3. Autoimmune disorders

Rpl31p63 has been shown to be involved in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Studies have shown that Rpl31p63 levels are higher in individuals with autoimmune disorders and that targeting Rpl31p63 may be a potential therapy.

4. Cellular processes

Rpl31p63 is involved in several cellular processes that are important for cell survival, including cell adhesion, migration, and survival. Studies have shown that Rpl31p63 plays a role in the regulation of cell-cell adhesion and that alterations in Rpl31p63 levels may affect cell behavior.

5. The potential implications of Rpl31p63 as a drug target or biomarker

The potential implications of Rpl31p63 as a drug target or biomarker are significant. If Rpl31p63 is indeed involved in multiple disease processes, targeting Rpl31p63 may be a potential therapy for a variety of diseases.

Targeting Rpl31p63

Targeting Rpl31p63 may involve a variety of techniques, including small molecule inhibitors, RNA-based therapeutics, and protein-based therapeutics. Small molecule inhibitors may be effective by blocking the activity of Rpl31p63, while RNA-based therapeutics and protein-based therapeutics may be effective by modifying the expression or function of Rpl31p63.

Conclusion

Rpl31p63 is a gene that has been shown to be involved in several disease-related processes, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential implications of Rpl31p63 as a drug target or biomarker are significant, and research into Rpl31p63 is an important area of study. Further research is needed to fully understand the role of Rpl31p63 in disease and to develop effective therapies for targeting Rpl31p63.

Protein Name: Ribosomal Protein L31 Pseudogene 63

The "RPL31P63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL31P63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets